City of San Antonio enacting plan to better leverage military medical assets

  The San Antonio Military Life Science Commercialization Action Plan seeks to better leverage ...

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Featured image is of SwRI staff working in their cGMP clean room where clinical supplies of their ...


Learn to Prepare IND for Small Molecule Drugs

How does a drug development program evolve from a brilliant research idea? Join Southwest Research Institute ...
San Antonio’s EO2 Concepts advancing new technology that could impact millions of diabetics
June 2, 2015

Courtesy of EO2 Concepts

By W. Scott Bailey, San Antonio Business Journal

A significant number of San Antonians are dealing with diabetes, so it's only fitting that an Alamo City company is advancing technology which could prove critical in helping treat diabetic wounds. EO2 Concepts has interim results from a new study which indicate that the company's TransCu O2 device provides more effective and less expensive treatment for millions of diabetics suffering from chronic wounds.

The TransCu O2 tissue oxygenation device is portable and allows for constant treatment without limiting patients' mobility. The device provides a continuous supply of low-flow pure oxygen which can help treat a variety of lower-limb wounds, including venous leg ulcers, diabetic foot ulcers and pressure ulcers.

Preliminary results from the new study suggest encouraging trends for patients receiving Continuous Diffusion of Oxygen, or CDO, therapy for such chronic wounds. Roughly 53 percent of patients receiving CDO therapy via the TransCu 02 device experienced complete wound closure in 12 weeks, an improvement over published results from other would-be therapies, according to EO2 Concepts officials.

Mark Niederauer, chief operating officer for EO2 Concepts, said CDO therapy is a "very promising therapeutic approach" that company officials believe could "transform the current standard of care" for millions of diabetics who struggle with chronic wounds. He said the therapy was found to have results equivalent or superior to other advanced treatments, yet is easier to apply and less costly.

While oxygen-based therapies have been proven to be effective in treating chronic wounds, the therapeutic approach to allow for 24-hour delivery of diffused oxygen is relatively new, according to officials with EO2 Concepts. Niederauer said the private company is proceeding with additional studies officials expect will further validate the efficacy of their technology.


Stay informed. Subscribe to BioMed SA news alerts.